In silico three-dimensional pharmacophores for aiding the discovery of the Pfmrk (Plasmodium cyclin-dependent protein kinases) specific inhibitors for the therapeutic treatment of malaria

Bibliography

• RIDLEY RG: Medical need, scientific opportunity and the drive for antimalarial drugs. Nature (2002) 415:686-693.
   PubMed Web of Science ®Google Scholar
• DOERIG C, MEIJER L: Antimalarial drug discovery: targeting protein kinases. Expert Opin. Ther. Targets (2007) 11(3):279-290.
   PubMed Web of Science ®Google Scholar
• DOERIG C, CHAKRABARTI D, KAPPES B et al.: The cell cycle in protozoan parasites. Prog. Cell Cycle Res. (2000) 4:163-183.
   PubMedGoogle Scholar
• MORGAN DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann. Rev. Cell Dev. Biol. (1997) 13:261-291.
   PubMed Web of Science ®Google Scholar
• MEIJER L, LECLERC S, LEOST M: Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. (1999) 82:279-284.
   PubMed Web of Science ®Google Scholar
• FISCHER PM, LANE DP: Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. (2000) 7:1213-1245.
   PubMed Web of Science ®Google Scholar
• O'HARE M, WANG F, PARK DS: Cyclin-dependent kinases as potential targets to improve stroke outcome. Pharmacol. Ther. (2002) 93:135-143.
   PubMed Web of Science ®Google Scholar
• MONACO EA, VALLANO ML: Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians. Curr. Med. Chem. (2003) 10:367-379.
   PubMed Web of Science ®Google Scholar
• IVORRA C, SAMYN H, EDO MD et al.: Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Curr. Pharm. Biotechnol. (2003) 4:21-37.
   PubMedGoogle Scholar
• CANDURI F, AZEVEDO WFD: Structural basis for interaction of inhibitors with cyclin-dependent kinase 2. Curr. Comput. Aided Drug Des. (2005) 1:53-64.
   Web of Science ®Google Scholar
• PAVLETICH NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. (1999) 287:821-828.
   PubMed Web of Science ®Google Scholar
• ENDICOTT JA, NOBLE MEM, TUCKER JA: Cyclin-dependent kinases: inhibition and substrate recognition. Curr. Opin. Struct. Biol. (1999) 9:738-744.
   PubMed Web of Science ®Google Scholar
• DOERIG C, ENDICOTT J, CHAKRABARTI D: Cyclin-dependent kinase homologues of Plasmodium falciparum. Int. J. Parasitol. (2002) 32:1575-1585.
   PubMed Web of Science ®Google Scholar
• HARMSE L, VAN ZYL R, GRAY N et al.: Structure–activity relationships and inhibitory effects of various purine derivatives on the in growth of Plasmodium falciparum. Biochem. Pharmacol. (2001) 62:341-348.
   PubMed Web of Science ®Google Scholar
• LI Z, LE ROCH K, GEYER JA et al.: Influence of human p16(INK4) and p21(CIP1) on the in activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases. Biochem. Biophys. Res. Commun. (2001) 288:1207-1211.
   PubMed Web of Science ®Google Scholar
• GRAESER R, FRANKLIN RM, KAPPES B: Mechanisms of activation of the cdc2-related kinase PfPK5 from i. Mol. Biochem. Parasitol. (1996) 79:125-127.
   PubMed Web of Science ®Google Scholar
• LE ROCH K, SESTIER C, DORIN D et al.: Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J. Biol. Chem. (2000) 275:8952-8958.
   PubMed Web of Science ®Google Scholar
• LI JL, ROBSON KJ, CHEN JL et al.: Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization. Eur. J. Biochem. (1996) 241:805-813.
   PubMedGoogle Scholar
• MERCKX A, LE ROCH K, NIVEZ MP, DORIN D et al.: Identification and initial characterization of three novel cyclin related proteins of human malaria parasite Plasmodium falciparum. J. Biol. Chem. (2003) 278:39839-39850.
   PubMed Web of Science ®Google Scholar
• WATERS NC, WOODARD CL, PRIGGE ST: Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum. Mol. Biochem. Parasitol. (2000) 107:45-55.
   PubMed Web of Science ®Google Scholar
• WOODARD CL, LI Z, KATHCART AK et al.: Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. J. Med. Chem. (2003) 46:3877-3882.
   PubMed Web of Science ®Google Scholar
• HONMA T, HAYASHI K, AOYAMA T et al.: Structure-based generation of a new class of potent Cdk4 inhibitors: new de nova design strategy and library design. J. Med. Chem. (2001) 44:4615-4627.
   PubMed Web of Science ®Google Scholar
• DE BONDT HL, ROSENBLATT J, JANCARIK J et al.: Crystal structure of cyclin-dependent kinase 2. Nature (1993) 363:595-602.
   PubMed Web of Science ®Google Scholar
• HARDCASTLE IR, GOLDING BT, GRIFFIN RJ: Designing inhibitors of cyclin-dependent kinases. Ann. Rev. Pharmacol. Toxicol. (2002) 42:325-348.
   PubMed Web of Science ®Google Scholar
• BROWN NR, NOBLE ME, LAWRIE AM et al.: Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. (1999) 274:8746-8756.
   PubMed Web of Science ®Google Scholar
• LEGRAVEREND M, TUNNAH P, NOBLE M et al.: Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. (2000) 43:1282-1292.
   PubMed Web of Science ®Google Scholar
• NOBLE ME, ENDICOTT JA: Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. Ther. (1999) 82:269-278.
   PubMed Web of Science ®Google Scholar
• VESELY J, HAVLICEK L, STRNAD M et al.: Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. (1994) 224:771-786.
   PubMedGoogle Scholar
• SCHULTZ C, LINK A, LEOST M et al.: Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. (1999) 42:2909-2919.
   PubMed Web of Science ®Google Scholar
• GRAY N, DETIVAUD L, DOERIG C: ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. (1999) 6:859-875.
   PubMed Web of Science ®Google Scholar
• SCHOEPFER J, FRETZ H, CHAUDHURI B et al.: Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem. (2002) 45:1741-1747.
   PubMed Web of Science ®Google Scholar
• KEENAN SM, GEYER JA, WELSH WJ et al.: Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Comb. Chem. High Throughput Screen. (2005) 8:27-38.
   PubMed Web of Science ®Google Scholar
• HOLTON S, MERCKX A, BURGESS D, DOERIG C, NOBLE M. et al.: Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Structure (Camb.) (2003) 11:1329-1337.
   PubMed Web of Science ®Google Scholar
• WATERS NC, GEYER JA: Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development. Expert Opin. Ther. Targets (2003) 7:7-17.
   PubMed Web of Science ®Google Scholar
• LEGRAVEREND M, TUNNAH P, NOBLE M et al.: Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. (2000) 43:1282-1292.
   PubMed Web of Science ®Google Scholar
• XIAO Z, WATERS NC, WOODARD CL et al.: Design and synthesis of Pfmrk inhibitors as potential antimalarial agents. Bioorg. Med. Chem. Lett. (2001) 11:2875-2878.
   PubMed Web of Science ®Google Scholar
• OU T, XU X: Recent development and application of virtual screening in drug discovery. Curr. Pharm. Des. (2004) 10:1011-1033.
   PubMed Web of Science ®Google Scholar
• LYNE PD: Structure-based virtual screening: an overview. Drug Discov. Today (2002) 7:1047-1055.
   PubMed Web of Science ®Google Scholar
• FOX T, HAAKSMA EEJ: Computer based screening of compound database:1 preselection benzamidine-based thrombin inhibitor. J. Comput. Aid. Mol. Des. (2000) 14:411-425.
   PubMed Web of Science ®Google Scholar
• WALTERS WP, STAHL MT, MURCKO MA: Virtual screening – an overview. Drug Discov. Today (1998) 3:160-178.
   Web of Science ®Google Scholar
• Guner O: Pharmacophore Perception, Development and Use in Drug Design. (Ed.) La Jolla, IUL Biotechnology Series CA, USA (2000).
   Google Scholar
• ACCELRYS: CATALYST; 4.7, San Diego, CA, USA (2003).
   Google Scholar
• CHEMICAL INFORMATION SYSTEM: Division of Experimental Therapeutics. Walter Reed Army Institute of Research, Silver Spring, MD, USA.
   Google Scholar
• EKINS S, WALLER CL, SWAAN PW et al.: Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods (2000) 44:251-272.
   PubMed Web of Science ®Google Scholar
• BHATTACHARJEE AK, GEYER JA, WOODARD CL et al.: A three-dimensional in pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel pfmrk specific inhibitors. J. Med. Chem. (2004) 47:5418-5426.
   PubMed Web of Science ®Google Scholar
• DE AZEVEDO WF, LECLERC S, MEIJER L et al.: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. (1997) 243:518-526.
   PubMedGoogle Scholar
• DE AZEVEDO WF Jr, MUELLER-DIECKMANN HJ, SCHULZE-GAHMEN U et al.: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA (1996) 93:2735-2740.
   PubMed Web of Science ®Google Scholar
• BROWN NR, NOBLE ME, LAWRIE AM et al.: Effects of phosphorylation of threonine 160 on cyclin dependent kinase 2 structure and activity. J. Biol. Chem. (1999) 274:8746-8756.
   PubMed Web of Science ®Google Scholar
• WATERS NC, DENNULL R, CORTES E et al.: Establishment of thiophene sulfonamides as novel inhibitors of the plasmodial cyclin dependent protein kinases (CDKs). Am. J. Trop. Med. Hyg. (2006) (Abstract #873).
   Google Scholar
• PARK H, YEOM MS, LEE S: Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4. Chem. Bio. Chem. (2004) 5:1662-1672.
   Google Scholar
• HEADY L, FERNANDEZ-SERRA M, MANCERA RL et al.: Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations. J. Med. Chem. (2006) 49:5141 -5153.
   PubMed Web of Science ®Google Scholar
• SKYLARIS CK, HAYNES PD, MOSTOFI AA et al.: C. Introducing one step: linear-scaling density functional simulations on parallel computers. J. Chem. Phys. (2005) 122:84-119.
   Google Scholar
• FILIKOV A: Kinase-likeness as viewed by chemists and by kinases. Cambridge Health Institute's Fifth Annual “Protein kinase targets: drug discovery and design” Meeting Abstracts (4 – 6 June 2007).
   Google Scholar
• PARGELLIS C, TONG L, CHURCHILL L et al.: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. (2002) 4:268-272.
   Google Scholar